Since the discovery of induced pluripotent stem cells (iPSCs) in 2006, a large and thriving research products market has emerged, largely because the cells are non-controversial and can be generated directly from adult cells. It is clear that iPSCs represent a lucrative market segment, because methods for commercializing this cell type are expanding every year and clinical studies investigating iPSCs are swelling in number. [Read more…]
CIRM’s iPSC Repository Closes, Marking the End of a Landmark Resource for Stem Cell Research
Sadly, in July 2025, the California Institute for Regenerative Medicine (CIRM) officially closed its iPSC Repository, marking the end of one of the world’s most comprehensive publicly funded collections of human induced pluripotent stem cell (hiPSC) lines. With the repository’s closure, these cells are no longer available for purchase or distribution, a development that has drawn wide attention and sadness across the global stem cell community. [Read more…]
Qihan Biotech’s QN-139b becomes First iPSC-derived CAR NK therapy for Autoimmune Disease
A new chapter is beginning for iPSCs: Qihan Biotech, a leading innovator in cell engineering, has reported the first clinical use of an induced pluripotent stem cell (iPSC)-derived CAR natural killer (NK) therapy in an autoimmune disease. The product, known as QN-139b, was administered to a patient with refractory systemic sclerosis (SSc), marking the first time an iPSC-derived CAR immune therapy has been used beyond oncology. [Read more…]
HeartBeat.bio and Boehringer Ingelheim Use Human iPSC-Based Cardioids to Model Inherited Cardiomyopathies
HeartBeat.bio Joins Forces with Boehringer Ingelheim to Advance Gene Therapies for Inherited Heart Muscle Disorders
Vienna, Austria – September 23, 2025 – HeartBeat.bio has entered into a research collaboration with Boehringer Ingelheim to develop gene therapy-based treatments for genetic cardiomyopathies. The partnership combines Boehringer Ingelheim’s expertise in gene therapy drug development with HeartBeat.bio’s proprietary Cardioid Drug Discovery Platform, aiming to advance innovative therapies for inherited heart muscle diseases. [Read more…]
uBriGene Unveils V2.0 RNA-LNP iPSC Reprogramming Kit Optimized for PBMCs and Hard-to-Reprogram Cells
GERMANTOWN, MD, September 17, 2025 –Â uBriGene Biosciences, a leader in CGT CDMO and iPSC manufacturing technology development, announced the launch of its 2nd-Generation iPSC Reprogramming Kit, powered by proprietary RNA-LNP technology. The kit is designed and proven to deliver best-in-class performance to reprogram peripheral blood mononuclear cells (PBMCs) to induced pluripotent stem cell (iPSC). [Read more…]
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 79
- Next Page »